lactobacillus reuteri (BGP014)
/ BioGaia
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
June 27, 2025
A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis
(clinicaltrials.gov)
- P1/2 | N=35 | Completed | Sponsor: BioGaia Pharma AB | Recruiting ➔ Completed | N=50 ➔ 35 | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024
Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
February 14, 2023
A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis
(clinicaltrials.gov)
- P1/2 | N=50 | Recruiting | Sponsor: BioGaia Pharma AB | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Dec 2023
Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
February 10, 2022
A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis
(clinicaltrials.gov)
- P1/2 | N=50 | Recruiting | Sponsor: BioGaia Pharma AB | Initiation date: Nov 2021 ➔ Feb 2022
Trial initiation date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
February 10, 2022
BioGaia Pharma announces First Patient Enrolled in Phase I Clinical Study Evaluating BGP014 in mild to moderate ulcerative colitis (AUCH-1).
(Cision)
- "BioGaia Pharma received formal approval from relevant authorities to proceed with both of its planned clinical trials during summer 2021. Investigational Medical Products were delivered to sites Q4 2021 and screening began. The first patient was enrolled into AUCH-1 in February 2022....The first step in this program is to look at safety, tolerability and preliminary efficacy of BGP014 in the approved Phase I multi-centre study with mild to moderately active UC patients that will take place in Sweden."
Trial status • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis
1 to 4
Of
4
Go to page
1